Keyword: Pear Therapeutics
Pear plans a traditional pharma go-to-market model for its third digital therapeutic Somryst, now under review at the FDA.
It wasn't just deals folks were buzzing about in meeting rooms, restaurants and hotel lobbies, as our top FierceBiotech and FiercePharma stories show.
As patients continue taking a more active role in healthcare, pharma's interest in digital therapeutics, already on a roll, will only accelerate.
Novartis and Pear are partnering again, this time in a go-to-market deal for FDA-approved digital products to treat drug abuse.
